持续抗VEGF治疗下立体定向放疗对新生血管性AMD的微血管异常与长期疗效
本研究对50例新生血管性年龄相关性黄斑变性(nAMD)患者在接受单次立体定向放疗(SRT)并继续抗VEGF治疗(治疗-延长方案)后随访3年。抗VEGF治疗间隔从基线4.24±0.66周延长至12个月时7.52±3.05周(p<0.001),24和36个月保持稳定;但24和36个月视力分别下降5.8±15.9和11.0±20.1个字母,36%患眼出现微血管异常(MVAs)。结论认为SRT可减少抗VEGF注射频率,但需密切随访,其实践方式、方案和剂量应重新讨论。
要点
- 单次SRT后抗VEGF治疗间隔从基线4.24周延长至12个月7.52周并维持至36个月。
- 24和36个月平均视力分别下降5.8和11.0个字母。
- 36%患眼出现MVAs,多位于旁中心凹下方和鼻侧区域。
核心结论
- 真实世界中低能量SRT与抗VEGF注射频率降低相关并持续至第3年。
- 但观察到视力下降和较多MVAs,建议密切随访并重新讨论SRT的使用、方案和剂量。
研究设计与样本
- 连续纳入50例nAMD患者,单次SRT后随访3年。
- 2年后进行安全性分析,包括标准化研究成像和基于阅读中心的图像分析。
主要发现
- 平均无复发抗VEGF治疗间隔从基线4.24±0.66周增至12个月7.52±3.05周(p<0.001),24个月7.40±3.17周(p=0.746),36个月6.89±3.00周(p=0.175)。
- 24和36个月平均视力变化分别为-5.8±15.9和-11.0±20.1个字母。
- 36%患眼在彩色眼底照相和/或荧光素血管造影上显示MVAs,最常位于旁中心凹下方和鼻侧区域。
关键数值与推荐
- 抗VEGF治疗间隔从基线4.24±0.66周延长至12个月7.52±3.05周(p<0.001)。
- 24个月间隔7.40±3.17周(p=0.746),36个月6.89±3.00周(p=0.175)。
- 24和36个月视力变化分别为-5.8±15.9和-11.0±20.1个字母。
- 36%患眼出现MVAs。
临床怎么用
- SRT可作为减少nAMD抗VEGF注射负担的辅助手段,但需密切监测视力及微血管异常。
- 真实世界应用时需重新评估最佳治疗方案和剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For treatment of neovascular age-related macular degeneration (nAMD), multiple intravitreal injections of drugs targeting vascular endothelial growth factors (VEGF) result in a high burden for patients and healthcare systems. Low-energy stereotactic radiotherapy (SRT) might reduce the anti-VEGF need. This study evaluated the long-term efficacy and safety of adjunct SRT to anti-VEGF injections in a treat-and-extend regimen in nAMD. METHODS: 50 consecutive patients were followed 3 years after single-session SRT, a safety analysis including standardised study imaging, and a reading centre based image analysis was performed after 2 years. RESULTS: After increase from baseline (4.24±0.66 weeks) to 12 months (7.52±3.05 weeks, p<0.001), mean recurrence-free anti-VEGF treatment interval remained stable at 24 (7.40±3.17, p=0.746) and 36 months (6.89±3.00, p=0.175). Mean visual acuity change was -5.8±15.9 and -11.0±20.1 letters at 24 and 36 months, respectively. 36% of eyes showed microvascular abnormalities (MVAs) on colour fundus photography and/or fluoresceine angiography most frequently located in parafoveal inferior and nasal regions. CONCLUSION: In real life, low-energy SRT was associated with a reduced anti-VEGF injection frequency through year 3. However, due to an observed visual acuity reduction and remarkable number of MVAs, a close follow-up of these patients is recommended. The real-life use, optimal treatment schedule and dose should be rediscussed critically.
引用
- Hatz K, Zimmermann F, Lazaridis E, et al. Microvascular abnormalities and long-term efficacy after stereotactic radiotherapy under continued intravitreal anti-VEGF treatment for neovascular AMD. Br J Ophthalmol. 2020. PMID: 33355151. doi:10.1136/bjophthalmol-2020-317563
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。